Counterfeit drugs (WHO/EDM, 1999, 61 p.): Selected further reading

Counterfeit drugs (WHO/EDM, 1999, 61 p.)

		(introductory text...)
		Executive Summary
		1. Introduction
		2. Overview of the problem
		3. Impact on public health
		4. Factors facilitating counterfeiting
		5. Developing national strategies
		6. Specific measures
		7. Assessment of the problem at the national level
		8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
		9. Test methods
		10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
		11. Conclusion
		References
		Selected further reading
		Acknowledgements
		Glossary

Selected further reading

Agreement on Trade-Related Aspects of Intellectual Property Rights, including Trade in Counterfeit Goods. Geneva, World Trade Organization, 1995.

Agreement of Preshipment Inspection. Geneva, World Trade Organization, 1995. Bulk pharmaceutical chemicals. London, Institute of Quality Assurance, 1992. (Pharmaceutical Quality Group Monograph).

Code of ethics. Pharmaceutical journal, 1992, 248: 545-556. Ethical criteria for medicinal drug promotion, World Health Organization, Geneva, 1988.

FIP guidelines for drug procurement. The Hague, International Pharmaceutical Federation, 1992.

Gilbert JJ. Educational handbook for health personnel, 6th ed. Geneva, World Health Organization, 1987 (WHO Offset Publication No. 35).

Good manufacturing practices for pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series No. 823).

Good pharmacy practice in community and hospital pharmacy settings. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report Geneva, World Health Organization, 1999, Annex 7 (WHO Technical Report Series No. 885).

Guidelines on good distribution practice of medicinal products for human use. Official Journal of European Communities, 1994 (94/C/63/03).

Hayes P, Kayne S, Martin T, McMurdo A. Use of professional self audit in pharmacy practice. Pharmaceutical journal, 1992, 249: 650-652.

Kenyon AS, Layloff TP. Screening of pharmaceuticals by thin-layer chromatography. Geneva, World Health Organization, 1995 (unpublished document PHARM/95.290).

National drug regulatory legislation: guiding principles for small drug regulatory authorities. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 8 (WHO Technical Report Series No. 885).

Niebruegge LD, Juhl WE. Physical characterization of tablets and capsules. St Louis, Food and Drug Administration, Division of Drug Analysis, 1990 (FDA/ORA/Laboratory Information Bulletin 3566).

Pharmaceutical distribution. London, Institute of Quality Assurance, 1990 (Pharmaceutical Quality Group Monograph).

Provisional guidelines on the inspection of pharmaceutical manufacturers. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report. Geneva, World Health Organization, 1992, Annex 2 (WHO Technical Report Series No. 823).

Research and development of rapid examinations of fake drugs 1993-1994. International Affairs Division, Minister's Secretariat, Ministry of Health and Welfare, Japan. Geneva, World Health Organization, 1996 (unpublished document PHARM/96.341).

Simple tests for drugs included in the WHO model list of essential drugs. Geneva, World Health Organization, 1995 (unpublished document PHARM/95.583/rev. 1).

Simple thin-layer chromatographic identification of active ingredients in essential drugs. Aulendorf, German Pharma Health Fund, 1994.

Statutory Committee: professional conduct. Pharmaceutical journal, 1969, 203: 472.

Statutory Committee. Three names to be removed from register. Pharmaceutical journal, 1973, 210:212.

The role of the pharmacist in the health care system. Report of a WHO consultative group, New Delhi, India, 13-16 December 1988 and Report of a WHO Meeting, Tokyo, Japan, 31 August-3 September 1993. Geneva, World Health Organization, 1994 (unpublished document WHO/PHARM/94.569).

Training programme in drug analysis for counterfeit pharmaceuticals. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirtieth report. Geneva, World Health Organization, 1987, Annex 3 (WHO Technical Report Series No. 748).

Wingfield J. Misconduct and the pharmacist. Pharmaceutical journal, 1990, 245:531-533.